Has anyone tested these blends as blends?

Almost none of them. Of the 39 mixed vials listed here, 3 was tested as a product instead of pieced together from its parts. That one is a licensed testosterone product that mixes several forms of testosterone (esters), not a peptide blend. For the other 36, every claim made for the mix is borrowed from studies of each ingredient on its own.

If each ingredient has evidence, does the blend have evidence?

No. Evidence for A and evidence for B is not evidence for A plus B. It says nothing about whether the two stay stable in one vial, whether their effects add up, cancel out or overlap, what ratio would be right, or what happens to side effects when both arrive at once. A study of the mix exists to answer those questions, and for these products nobody ran one.

Why does the mass share matter?

Because it tells you what you are mostly injecting. A vial can list four ingredients and still be, by weight, one ingredient with three garnishes. The share on each card below is worked out from the label amounts, so you can see what the vial is mostly made of before you read what it is sold for.

How do I work out what one draw delivers from a blend?

Use blend mode in the reconstitution calculator. It takes each ingredient's label amount, the water you added and the draw you plan, and gives the amount of every ingredient in that draw separately. One strength figure means nothing when the vial holds several compounds at different amounts.

Why are some vial amounts missing here?

Because sellers do not agree on them. 22 of the 39 have no vial size consistent enough to quote, so the amount is left blank rather than invented. A made-up milligram figure would produce a made-up mass share, and the share is the part of this page worth reading.

Parts named, not ranked

36 of these 39 vials have never been tested as a vial

That is the most useful fact about these products, so it goes first. A blend is sold on the strength of its ingredients. Those ingredients were studied one at a time, mostly in animals. Nobody tested the mix. Nobody checked whether the ingredients stay stable together in one vial, whether their effects add up or overlap, or what ratio a person should want. The product exists. A study of the product does not.

Below are the 39 blends on this site, made from 40 different compounds. Each card shows what is in the vial, what share of the powder each ingredient is (where we could find a label weight), what the evidence for each ingredient actually supports, and the specific problem that mix creates. Exactly 3 of them carries a tested badge, and it is worth seeing why: multi-ester testosterone blends, semaglutide with cagrilintide, thymalin with epitalon.

Plate 14

Blend map

Parts named, not ranked

Blends

parts

Named on the page

A blend page names the parts and the evidence for each. It does not invent a grade for the mix.

Blends listed: 39; 40 different compounds between them
Tested as a combination: 3 of 39; the rest lean on studies of each ingredient alone
Label weight found: 17 of 39; 22 have no consistent vial size to quote

The 39 blends, and what is in them

Amounts are the milligram figures printed on common labels, never doses. The share beside each one is worked out from those figures. It shows what the vial is mostly made of, not what the name plays up.

KLOWNone

4 ingredients · 80 mg on the label

Never tested as a combination

GHK-Cu50 mg · 63% of the weight
A copper peptide tested in small studies as a cream on skin. Here it is most of the powder, and a copper dose you take again and again.
KPV10 mg · 13% of the weight
A small piece of a skin hormone called alpha-MSH. Given alone to mice with an inflamed gut, it lowered signs of inflammation.
BPC-15710 mg · 13% of the weight
Animal data on tendon and gut repair, plus one look back at twelve knee patients.
TB-50010 mg · 13% of the weight
Sold as thymosin beta 4. Lab tests found it is a seven amino acid piece of it.

What is known: Each of the four has its own studies, and every one tested it alone. GHK-Cu has skin cream work. KPV has mice with an inflamed gut. BPC-157 has animal repair studies. The piece inside TB-500 has lab work on how it binds actin, a protein cells use to move and build.
The catch: GHK-Cu is most of the vial by weight. So this is mostly a copper peptide product, whichever part you came for. The ratio is fixed, so taking less copper means taking less of the other three too.

Blend calculator

GLOWNone

3 ingredients · 70 mg on the label

Never tested as a combination

GHK-Cu50 mg · 71% of the weight
The skin claim in the product. Its human evidence is from creams used for looks, not shots.
BPC-15710 mg · 14% of the weight
Animal repair data and one small human report with nobody to compare against.
TB-50010 mg · 14% of the weight
The piece of thymosin beta 4 that binds actin, with no human trial of its own.

What is known: GHK-Cu has the better record for skin. It comes from small cream studies that measured how skin looked. The two healing peptides bring animal data on tissue repair.
The catch: It is KLOW without the KPV, and it is still mostly copper by weight. So a product bought for skin puts most of its milligrams into a peptide whose skin evidence came from putting it on the skin, not under it.

Blend calculator

WolverineNone

2 ingredients · 20 mg on the label

Never tested as a combination

BPC-15710 mg · 50% of the weight
The bigger half of the claim. A 2025 review found 36 studies, and 35 of them were in animals or cells.
TB-50010 mg · 50% of the weight
Sold as thymosin beta 4. A lab test on the product found Ac-LKKTETQ, just seven of its 43 amino acids.

What is known: Two separate sets of repair studies in animals and cells. One of them is large, in animals. Each part has trials in people registered on its own. None is registered for the pair.
The catch: The thymosin beta 4 research that sells this vial is about a molecule the vial does not contain. And with an even split, you cannot keep the part you believe in and drop the one you do not.

Blend calculator

CJC-1295 with ipamorelinNone

2 ingredients · 10 mg on the label

Never tested as a combination

CJC-12955 mg · 50% of the weight
The half that copies the brain's growth hormone release signal, called GHRH. It makes each growth hormone pulse bigger.
Ipamorelin5 mg · 50% of the weight
The half that works like the hunger hormone ghrelin. Sellers pick it because it releases growth hormone with less effect on cortisol and prolactin than older peptides of its type.

What is known: Each half has human studies showing it raises growth hormone on its own. They work through two different switches in the body. That is the reason the pair is sold at all.
The catch: Most vials labelled CJC-1295 without DAC hold mod GRF 1-29, so the name on the vial may not match what is inside. Both halves push the same growth hormone system, so any change in IGF-1 belongs to the pair, not to either part. Vials are also sold at ten and ten, so read the label rather than trusting the ratio here.

Blend calculator

Tesamorelin with ipamorelinNone

2 ingredients · no consistent label weight

Never tested as a combination

Tesamorelinamount not sourced
The one growth hormone releasing peptide in this group that is approved. It has large final stage trial data on deep belly fat.
Ipamorelinamount not sourced
A peptide that works like the hunger hormone ghrelin. It has short human studies on how the body handles it, and no trial of real health results.

What is known: Tesamorelin has the strongest record of any single part on this page apart from testosterone. It is approved, it has large final stage trials, and it has a set daily dose for cutting deep belly fat in people with HIV whose body fat has shifted.
The catch: That evidence is for tesamorelin taken alone at its own dose. A compounder's ratio puts you outside the only data that made it worth using. There is no standard vial size, though 5 mg plus 5 mg and 10 mg plus 3 mg are both common. The compound page does the math for those. Here is the sharp part. On a 5 plus 5 vial, you cannot reach the 2 mg of tesamorelin behind the approved result without also taking 2 mg of ipamorelin. That is roughly seven to ten times what anyone takes on purpose.

Blend calculator

NAD+ with B-complexNone

2 ingredients · no consistent label weight

Never tested as a combination

NAD+amount not sourced
The headline part. Human trials show blood NAD goes up after taking it. The evidence for what that changes is much thinner.
Vitamin B12amount not sourced
The one part here with a blood test that tells you if you need it. There are decades of evidence for fixing a shortage.

What is known: Giving B12 to someone low in it is settled medicine, and you can measure it before and after. The pills that the body turns into NAD have human trials that raise blood NAD. The evidence that this rise brings the energy and anti ageing benefits used to sell it is much weaker.
The catch: Two parts with opposite quality of evidence come in one syringe. So if you are low in B12, that is the half you feel, and the half being marketed takes the credit. There is no standard mix, though 250 to 500 mg of NAD+ with a 1,000 mcg B12 add on is the common drip. The compound page does that math, and B12 is about two tenths of one percent of it by weight. The B6 in a B-complex shot is pyridoxine. That is the form of B6 behind the reported nerve damage cases, which is worth knowing before it is added to anything.

Semax with selankNone

2 ingredients · no consistent label weight

Never tested as a combination

Semaxamount not sourced
A piece of the stress hormone ACTH. Doctors in Russia use it for stroke and thinking problems. Nearly all its studies are in Russian.
Selankamount not sourced
A copy of a small immune peptide called tuftsin. It is used in Russia for anxiety. It has small Russian trials and has not been repeated in the West.

What is known: Both are registered medicines in Russia and used there by doctors. Semax is for stroke and thinking, and selank is for anxiety. That is more than most peptides on this site can claim.
The catch: One is sold as a pick me up and the other as calming. So the blend puts two opposite goals in one draw, at a ratio the seller chose and you cannot change. Vial sizes differ between sellers, so you cannot tell the balance between them from the outside.

Sermorelin with a GHRPNone

2 ingredients · no consistent label weight

Never tested as a combination

Sermorelinamount not sourced
A piece of the growth hormone release signal, GHRH. It was once an approved product for growth hormone testing and for children, before the maker stopped selling it.
GHRP-2 or GHRP-6amount not sourced
The half that works like the hunger hormone ghrelin. It is usually GHRP-2 and sometimes GHRP-6, which raises appetite more of the two.

What is known: Sermorelin was an approved medicine, and GHRP-2 has human evidence that it causes a growth hormone pulse. Pairing a GHRH copy with a ghrelin copy is the oldest version, in this group, of the idea of hitting two switches at once.
The catch: Which GHRP you got changes how it feels. These peptides raise appetite, cortisol and prolactin by different amounts. A fixed blend gives you no way to keep the sermorelin while cutting back the GHRP when that shows up. Sellers do not publish steady vial sizes for either half.

Blend calculator

Multi-ester testosterone blendsNone6 reported

4 ingredients · 250 mg on the label

Tested as a combination

Testosterone propionate30 mg · 12% of the weight
The short acting form. It releases within a day or two and covers the start of the gap between shots.
Testosterone phenylpropionate60 mg · 24% of the weight
A medium acting form that bridges the first few days.
Testosterone isocaproate60 mg · 24% of the weight
A second medium acting form that releases a little more slowly.
Testosterone decanoate100 mg · 40% of the weight
The long acting form. It is the biggest share of the vial and carries the back end of the gap between shots.

What is known: The exception on this page. The four part mix is a licensed medicine in the United Kingdom and many other countries. So the mix itself was tested, not just pieced together. And the hormone it delivers has the largest safety trial on this site.
The catch: Every form breaks down to the same testosterone. So the milligrams on the label count the weight of the attached chain, not just the hormone. With four release speeds, a blood level depends on which forms were still releasing when the blood was drawn. A single form, taken weekly or split, does the same job and gives a blood result you can read.

Deadpool blendNone

3 ingredients · 30 mg on the label

Never tested as a combination

BPC-15710 mg · 33% of the weight
The repair claim. A 2025 review found 35 of its 36 studies were in animals or cells.
TB-50010 mg · 33% of the weight
Sold as thymosin beta 4. A drug testing lab found it is a seven amino acid piece of it.
KPV10 mg · 33% of the weight
A small piece of the skin hormone alpha-MSH. It has data in mice with an inflamed gut and no registered human study.

What is known: Three separate sets of studies, each on one peptide alone, all in animals or the lab. BPC-157 has rodent repair studies. The piece inside TB-500 has lab work on how it binds actin. KPV has mice with an inflamed gut.
The catch: The name is the danger. Sellers sell at least three different formulas as Deadpool. One is KLOW with copper, under a new label. Another uses a different third peptide. So the word tells you nothing. On the even split the schedules also clash. BPC-157 clears in under half an hour and is taken daily. The fragment is taken weekly, in milligrams. And one plunger sets both.

BPC-157 with KPVNone

2 ingredients · 20 mg on the label

Never tested as a combination

BPC-15710 mg · 50% of the weight
The repair half, first found in stomach juice research. The FDA counted five small human studies, and none gave it as a shot under the skin.
KPV10 mg · 50% of the weight
The half meant to calm inflammation. It has mouse gut results and no human data of any kind.

What is known: Both parts are aimed at the gut, which makes this the best argued idea in the seller catalogue. In gut cells, KPV turns down a main inflammation switch called NF-kB. It helped in two mouse models of an inflamed gut. BPC-157 has rodent data on protecting the gut.
The catch: The idea makes sense on paper. The evidence does not. KPV has zero registered human studies. Both parts have their best evidence where the peptide touches gut tissue directly, but this product is sold as a shot under the skin. Some sellers sell 5 plus 5 rather than 10 plus 10, so your label decides the math.

PDA with TB-500None

2 ingredients · no consistent label weight

Never tested as a combination

Pentadeca arginateamount not sourced
A salt form of the BPC-157 sequence, made with arginine. PubMed has no paper under that name, in any species.
TB-500amount not sourced
Sold as thymosin beta 4. A lab test found the product was Ac-LKKTETQ, seven of its 43 amino acids.

What is known: Nothing is published under either product's own name. The claims are borrowed twice. They come from BPC-157, whose sequence PDA shares, and from thymosin beta 4, which the other part is a piece of.
The catch: The one selling point that sets PDA apart from BPC-157 is that it is more stable. That is also the one claim with no data behind it either way. Vial sizes differ between sellers and there is no standard split, so this page gives no amount per unit. The schedules clash whatever the split, since one part is taken daily and the other weekly.

Quad healing blendNone

4 ingredients · 25 mg on the label

Never tested as a combination

TB-5005 mg · 20% of the weight
The actin binding piece, with no human study by any route.
BPC-1575 mg · 20% of the weight
Rodent repair data plus five small human studies, none as a shot under the skin.
KPV10 mg · 40% of the weight
Double the amount of the others here. It has mouse gut data and no human studies.
GHK-Cu5 mg · 20% of the weight
A fifth of the copper in a standard KLOW vial, at about 0.8 mg of copper itself rather than 7.9 mg.

What is known: It has the same four sets of single peptide studies as KLOW. They are a skin cream study that failed when the checkers did not know who got it, mice with an inflamed gut, rodent repair studies, and a piece of a different protein.
The catch: The ingredient list is not the product. This vial and KLOW share four ingredients but differ more than threefold in copper share, 20% here against 62.5%. Nothing in the name tells a buyer which one they have. The ratio is still fixed, so you cannot lower the copper without lowering whatever else you bought the vial for.

GLOW capsulesNone

3 ingredients · 3 mg on the label

Never tested as a combination

GHK-Cu2 mg · 67% of the weight
The skin claim, per capsule. All of its human evidence is a cream on skin.
BPC-1570.5 mg · 17% of the weight
Half a milligram per capsule, taken by mouth, with no published data on whether it gets absorbed.
TB-5000.5 mg · 17% of the weight
The seven amino acid piece, with no human study by any route, let alone swallowed.

What is known: Nothing has tested any of the three this way. GHK-Cu's human record is creams on skin. BPC-157's five human studies were not shots under the skin and not capsules. The piece has never been given to a person.
The catch: Do the math and the product changes shape. The three peptides add up to 3 mg per capsule, against about 100 mg of hyaluronic acid. So roughly 97% of what you swallow is a cheap skin care ingredient that holds water. It is the ingredient most likely to be behind anything a user notices. Nobody has published whether any of the three peptides survives the stomach.

CJC-1295 with GHRP-2None

2 ingredients · 10 mg on the label

Never tested as a combination

CJC-1295 (no DAC)5 mg · 50% of the weight
The GHRH copy half, which makes each pulse bigger. Most no-DAC material is mod GRF 1-29, not the molecule with the published data on how long it lasts.
GHRP-25 mg · 50% of the weight
The ghrelin copy half. It has a 30 day drip study and a measured rise in how much healthy men ate.

What is known: These two drug types have real data together. A 24 hour drip of GHRP-2 with GHRH pushed growth hormone higher than either one alone in healthy older adults. The boost was three times greater in the young, and 2.3 times higher in older women than in older men. That used GHRH by drip in a research setting, not this vial.
The catch: The problem is what is in the vial. The published CJC-1295 numbers, a half life of 5.8 to 8.1 days and a six day rise in growth hormone, describe the DAC version, which has an add on that makes it last. The no-DAC material in these vials works for minutes. So a buyer quoting that half life is off by a huge amount. GHRP-2 also raises appetite by a measurable amount, and the fixed ratio means you cannot cut it back while keeping the GHRH half.

CJC-1295 with GHRP-6None

2 ingredients · no consistent label weight

Never tested as a combination

CJC-1295 (no DAC)amount not sourced
The GHRH copy half. How long it really lasts depends on which molecule is actually in the vial.
GHRP-6amount not sourced
The GHRP that raises hunger the most. Human data on how the body handles it comes from nine male volunteers. Half of it is cleared in about 2.5 hours.

What is known: GHRP-6 has a published human study of how the body handles it. It spread through the body with a half life of about 7.6 minutes and was cleared with a half life of about 2.5 hours. In four of nine men, blood levels spiked oddly while it was clearing. A GHRP paired with GHRH has been shown to beat GHRH alone, using GHRP-2 by drip.
The catch: If the vial holds the DAC version, one part lasts a hundred times longer than the other. If it holds mod GRF 1-29, both clear within hours. One fixed ratio cannot be right for both, and the buyer usually cannot tell which they have. GHRP-6 raises appetite because of how it works, not because of a bad batch, and you cannot turn that down on its own. Sellers do not agree on vial sizes.

Sermorelin with ipamorelinNone

2 ingredients · no consistent label weight

Never tested as a combination

Sermorelinamount not sourced
GHRH 1-29, once an approved product, with data in children who lacked growth hormone.
Ipamorelinamount not sourced
The ghrelin copy half, picked for less effect on cortisol, prolactin and appetite than older GHRPs. Its one trial against a dummy did not reach its main goal.

What is known: Sermorelin was an approved medicine. It was compared against growth hormone itself in children who lacked growth hormone. Ipamorelin has one trial against a dummy drip. It gave the drug by vein to 117 people after bowel surgery. It was safe, and it did not beat the dummy on how soon people could eat a solid meal.
The catch: A prescription changes where the vial comes from, not the evidence. Pharmacy mixed products are not FDA approved and are not checked for safety or whether they work. Pharmacies sell several strengths and fill amounts, so there is no standard size and the math has to come from your own label. Both halves push the same nightly pulse, so IGF-1 shows you the pair and never the parts.

CJC-1295 with ipamorelin and GHRP-2None

3 ingredients · 6 mg on the label

Never tested as a combination

CJC-1295 (with DAC)2 mg · 33% of the weight
The only part in the vial that works a truly different way. It is the one with a published half life of 5.8 to 8.1 days.
Ipamorelin2 mg · 33% of the weight
A ghrelin copy chosen because it raises cortisol and prolactin less.
GHRP-22 mg · 33% of the weight
A second ghrelin copy, hitting the same switch, which brings back the appetite effect ipamorelin is meant to avoid.

What is known: Only the pairing of one GHRP with a GHRH peptide has data as a combination. It comes from a 24 hour drip study in healthy older adults. Nothing supports adding a second peptide that hits the same switch.
The catch: Three ingredients, two ways of working, one of them given twice. At a 10 unit draw from a vial mixed with 2 mL of water, you take 100 micrograms of each. That is 200 micrograms of ghrelin copy combined, and the label never shows it that way. The spread in how long they last makes the schedule impossible. Daily dosing builds up the long lasting part, and weekly dosing wastes the two short ones.

MK-677 with ipamorelinNone

2 ingredients · no consistent label weight

Never tested as a combination

MK-677 (ibutamoren)amount not sourced
The pill half, and the only one in this group with a two year trial against a dummy pill. Lean mass rose 1.1 kg, while the dummy pill group lost 0.5 kg.
Ipamorelinamount not sourced
The shot half, hitting the same switch. Its one trial against a dummy did not reach its main goal.

What is known: In a two year trial, 65 healthy adults aged 60 to 81 took 25 mg of MK-677 a day. Growth hormone and IGF-1 rose back to young adult levels. Lean mass rose 1.1 kg, while the dummy pill group lost 0.5 kg. It did not clearly help strength or physical function.
The catch: Both work on the same ghrelin switch, so this is one way of working given twice, not two. One keeps growth hormone raised around the clock. The other makes a pulse. Those are different states in the body, and nobody has measured what a pulse on top of a raised baseline does. Lean mass includes water, and keeping the ghrelin switch on all day causes water retention.

Sermorelin with GHRP-2 and GHRP-6None

3 ingredients · 9 mg on the label

Never tested as a combination

Sermorelin3 mg · 33% of the weight
The GHRH half, and the only part with a history of approval, in children who lacked growth hormone.
GHRP-23 mg · 33% of the weight
A ghrelin copy with a 30 day drip study and a measured rise in how much healthy men ate.
GHRP-63 mg · 33% of the weight
A second ghrelin copy on the same switch, and the one that raises hunger the most.

What is known: One GHRP paired with GHRH has combination data. A 24 hour drip of GHRP-2 with GHRH pushed growth hormone above either one alone in healthy older adults. Sermorelin has data from its approval years in children. GHRP-6 has single dose human data showing half of it is cleared in about 2.5 hours.
The catch: The label shows three equal thirds. But the body sees a two to one split, because both GHRPs hit the same ghrelin switch and add up there. At a 20 unit draw from a vial mixed with 3 mL of water, that is 200 micrograms of sermorelin against 400 micrograms of ghrelin copy combined, and both GHRPs raise appetite. Also sold as a 6 mg vial at 2 mg each.

Semaglutide with B12None

2 ingredients · no consistent label weight

Never tested as a combination

Semaglutideamount not sourced
The half with the evidence. In STEP 1, people lost 14.9% of their weight on average at 68 weeks, against 2.4% on a dummy shot. No vitamin was used.
Cyanocobalaminamount not sourced
Kept at 0.5 mg/mL at every strength. So how much B12 you get is set by your semaglutide dose, not by your B12 level.

What is known: Semaglutide at 2.4 mg a week cut weight by 14.9% on average at 68 weeks, against 2.4% on a dummy shot. B12 given to people low in it brings blood B12 back to normal in over 90% of them at eight weeks, by pill or shot. Neither result involved the other ingredient.
The catch: The math is the story. The B12, as cyanocobalamin, sits at 0.5 mg/mL, while semaglutide comes at 1 or 5 mg/mL. On the strong mix, a 0.5 mg dose carries 50 micrograms of B12 and a 2.4 mg dose carries about 240. On the weak mix, that same 0.5 mg dose carries 250. That is five times more B12 for the same semaglutide. It rises every time you step up the dose, and nothing about you sets it. No trial supports the claim that the B12 helps nausea or tiredness.

Tirzepatide with B12None

2 ingredients · no consistent label weight

Never tested as a combination

Tirzepatideamount not sourced
20 mg/mL in the common multi dose mix. Alone, on 15 mg, it cut weight by 20.9% on average at 72 weeks, against 3.1% on a dummy shot.
Cyanocobalaminamount not sourced
0.5 mg/mL, so 2.5% of the peptide by weight at every dose. It is the part tied to the published impurity finding.

What is known: Tirzepatide alone has SURMOUNT-1 behind it. In that trial, 57% of the 15 mg group lost 20% or more of their body weight at 72 weeks. B12 works in people a blood test shows are low. The premix itself has no clinical study.
The catch: This is the one blend on this site with a published chemical reason not to mix it. Lab testing of pharmacy mixed tirzepatide plus B12 products, from several US sources, found a new impurity in many of them. It forms when the peptide reacts with certain forms of B12. The authors say plainly that its effects in the body are unknown. Every author worked for the maker of the brand name drug. That conflict was disclosed and it is real. No independent group has repeated or challenged the work.

Semaglutide with BPC-157None

2 ingredients · no consistent label weight

Never tested as a combination

Semaglutideamount not sourced
An approved drug. People on it lost 12.4 percentage points more weight than on a dummy shot at 68 weeks.
BPC-157amount not sourced
Not approved, not allowed as a pharmacy mixing ingredient, and found by FDA staff in 2026 to have no adequate human data.

What is known: Semaglutide has STEP 1. BPC-157 has five human studies with fewer than 110 people in total. None gave it as a shot under the skin and none ran longer than two weeks. The two reasons given for the pair, cutting GLP-1 nausea and keeping muscle, have no trial behind them in any species.
The catch: Losing muscle on these drugs is a real problem, and this is not the answer to it. No study in any species has measured whether BPC-157 keeps lean mass while eating less. The nausea claim cannot really be tested, since GLP-1 nausea fades over the first weeks whether or not you add anything. And the schedules do not fit. One is weekly, and the other is reported to clear in under half an hour.

Tirzepatide with BPC-157None

2 ingredients · no consistent label weight

Never tested as a combination

Tirzepatideamount not sourced
The half with a large trial and an approval.
BPC-157amount not sourced
The half the FDA found had no adequate human data, with mislabelled products on the market.

What is known: Tirzepatide on 15 mg cut weight by 20.9% on average at 72 weeks, against 3.1% on a dummy shot. BPC-157's human record is five small studies by routes nobody uses. Nothing describes the two together in any species.
The catch: Two problems stack up. Legally, BPC-157 is not allowed as a pharmacy mixing ingredient, so a premixed product is unlawful because of its second ingredient, whatever the first. Chemically, the only published lab test of tirzepatide premixed with anything found a new substance formed by a reaction. And that other thing was a vitamin, not an untested research peptide.

Retatrutide with cagrilintideNone

2 ingredients · 15 mg on the label

Never tested as a combination

Retatrutide12.5 mg · 83% of the weight
83.3% of the vial by weight. Alone, on 12 mg, it cut weight by 24.2% on average at 48 weeks. Heart rate went up more at higher doses.
Cagrilintide2.5 mg · 17% of the weight
16.7% of the vial. Alone it cut weight by 6.0% to 10.8% across doses at 26 weeks, against 3.0% on a dummy shot.

What is known: Each part has solid early trial data on its own. Pairing an amylin drug with a GLP-1 type drug has been tested, and it worked. Cagrilintide with semaglutide reached 20.4% weight loss on average at 68 weeks in 3,417 people. That used a drug that hits only GLP-1, not a triple drug like retatrutide.
The catch: Neither drug is approved anywhere, so every vial comes from a research chemical seller with no pharmacy involved. The fixed 5 to 1 ratio is the sharp problem. Retatrutide's trial stepped up from 2 mg to 12 mg because the gut side effects got worse with dose. In a fixed blend, holding or cutting one part cuts the other by the same share, whether or not it caused the problem. Some sellers sell 10 plus 2.5, so the split is not standard.

Semaglutide with cagrilintideNone

2 ingredients · no consistent label weight

Tested as a combination

Semaglutideamount not sourced
The GLP-1 half. Alone it cut weight by 14.9% on average at 68 weeks in STEP 1.
Cagrilintideamount not sourced
The amylin half. Alone it cut weight by 6.0% to 10.8% at 26 weeks. Blood levels rise in step with the dose, and it does not change semaglutide levels.

What is known: The exception in this group. REDEFINE 1 put 3,417 people into groups. The pair cut body weight by an estimated 20.4% on average at week 68, against 3.0% on a dummy shot. That is a gap of 17.3 percentage points. An earlier small trial had already stepped up both drugs together over 16 weeks in 96 people. Cagrilintide levels rose in step with the dose and did not change semaglutide levels.
The catch: The trial result belongs to a drug company product with set ratios, a set plan for raising the dose, and doctor supervision. A seller's blend shares the idea and none of those conditions, and the ratio is the seller's choice, not the trial's. The cost is also part of the result and rarely quoted. Gut side effects hit 79.6% of the pair group, against 39.9% on the dummy shot.

Argireline with Matrixyl and SNAP-8None

3 ingredients · no consistent label weight

Never tested as a combination

Acetyl hexapeptide-8 (Argireline)amount not sourced
The only part with its own trial against a dummy cream: 60 people, four weeks, and roughness measured on a silicone mould of the skin went down.
Palmitoyl peptides (Matrixyl)amount not sourced
A supplier's trade name blend of palmitoyl peptides, with no independent trial against a dummy.
Acetyl octapeptide-3 (SNAP-8)amount not sourced
Sold as a longer cousin of argireline, with no independent trial against a dummy.

What is known: Judged by eye, the argireline group had 48.9% overall wrinkle improvement, against 0% on the dummy cream, in 60 people. Skin roughness measured on a silicone mould fell in the treated group only. Across the whole field, a review of 19 trials in 1,341 people found a small pooled effect on wrinkles, an average difference of 0.27. Most of that came from peptides taken by mouth, not creams.
The catch: The percentage on the bottle is almost never the peptide. These ingredients reach brands as weak trade name liquids that are mostly water, glycerin and preservative. So a printed percentage usually describes the supplier's liquid, and most brands do not say which they mean. Where the real peptide amount is not published, you cannot know how much you get per use, and this entry gives none.

GHK-Cu with zinc thymulinNone

2 ingredients · no consistent label weight

Never tested as a combination

GHK-Cuamount not sourced
Commonly 5 mg/mL, so 500 times the thymulin by weight. Its human evidence is creams on skin, about skin rather than hair.
Zinc thymulinamount not sourced
Commonly 10 micrograms/mL. The hair evidence is human scalp hair roots kept alive in a dish, reported in a short research letter.

What is known: Thymus peptides, including thymulin, changed how human scalp hair roots grew when kept alive in a dish. GHK-Cu's human data is creams on skin, and its main trial failed when checked by raters who did not know who got what. In 13 people after laser skin treatment, there was no real difference in redness, wrinkles or skin quality.
The catch: The ratio flips the product. At 5 mg/mL against 10 micrograms/mL, a 1 mL dose gives 5 mg of copper peptide and 10 micrograms of the thymus peptide. And it is the thymus peptide that has the hair root evidence. The copper peptide also carries roughly 0.8 mg of copper per millilitre, which is what stains pillowcases. Neither part has a trial for hair in people.

AHK-Cu with GHK-CuNone

2 ingredients · no consistent label weight

Never tested as a combination

AHK-Cuamount not sourced
One 2007 study, on human hair roots kept alive in a dish, where they grew longer. Never tested in people.
GHK-Cuamount not sourced
Small human cream data that failed when checked by raters who did not know who got what, plus gene and cell work.

What is known: Only one of the two has any studies. GHK-Cu has human cream data and gene work in a dish. Its trial in 13 people after laser skin treatment found no real difference in redness, wrinkles or overall skin quality, as judged by raters who did not know who got what.
The catch: This is borrowing evidence in its clearest form. A molecule with no papers under its own name sits beside a similar one that has some, and the group name lets the second cover both. Both carry copper, so the serum just has more copper peptide, not two ways of working. Brands do not agree on strengths and many print trade blend percentages, so no amount per use is given here.

Melanotan II with PT-141None

2 ingredients · no consistent label weight

Never tested as a combination

Melanotan IIamount not sourced
A peptide that hits many of the body's melanocortin switches. In ten men, 8 of 10 got erections. Erections firmer than 80% at the tip lasted 38.0 minutes, against 3.0 on a dummy shot.
Bremelanotide (PT-141)amount not sourced
An approved medicine for low sex drive in women before menopause. It is also what the body breaks the other part down into.

What is known: Both have human trials. Melanotan II produced erections in ten men whose erection problems had no physical cause, and each man tried both it and a dummy shot. Bremelanotide has two large final stage trials in women behind its approval.
The catch: Bremelanotide is a breakdown product of melanotan II. So stacking them is one drug action at a higher total dose, not two. Nausea comes with this whole drug type and shows up in the trials with dummy groups. The specific harm is to the skin. Melanotan II darkens existing moles along with everything else. That hides the change in a mole that is the main early warning sign of melanoma. There is no standard vial size.

PT-141 with oxytocinNone

2 ingredients · 15 mg on the label

Never tested as a combination

Bremelanotide (PT-141)10 mg · 67% of the weight
Two thirds of the vial by weight, and the half with an approval and two large final stage trials.
Oxytocin acetate5 mg · 33% of the weight
One third of the vial. In the trial that tested it for sexual problems, it did not beat a dummy on anything.

What is known: Bremelanotide has two large final stage trials in women before menopause with low sex drive. Oxytocin was tested in 30 women, who each tried it and a dummy nose spray without knowing which was which. A sexual function score rose 26% on oxytocin and 31% on the dummy. Distress fell 36% and 45%. There was no real difference between them.
The catch: The oxytocin half failed its own trial. And in that trial it was a nose spray, because oxytocin given as a shot reaches the brain poorly. This vial is a shot, the route least likely to reach the brain. Mixed with 3 mL of water, drawing the approved 1.75 mg of bremelanotide takes about 53 units. That also gives about 0.88 mg of oxytocin, an amount set by the seller's ratio rather than chosen as a dose.

Semax with selank and dihexaNone

3 ingredients · no consistent label weight

Never tested as a combination

Semaxamount not sourced
A registered medicine in Russia. The work on how it acts is in rats: a 1.4-fold rise in the brain growth protein BDNF in the memory part of the brain after one dose of 50 micrograms per kilogram.
Selankamount not sourced
The best clinical record of the three. In 62 patients with anxiety and nervous exhaustion, it calmed anxiety about as well as the drug medazepam.
Dihexaamount not sourced
The paper that showed how it acts was retracted in 2025, after a warning notice in 2021.

What is known: Selank has a clinical trial against a benzodiazepine type anxiety drug. Semax is registered and used by doctors in Russia, with rodent work behind the thinking claim. Both sets of Russian studies have not been repeated outside Russia.
The catch: One third of the stack rests on a retracted paper. The journal posted a warning notice in 2021 and retracted the dihexa paper in 2025. Several of its authors were tied to a company developing the drug. Separately, one part is sold as a pick me up and one as calming. So the seller has fixed the balance between stimulating and sedating for every buyer. There is no standard vial size.

DSIP with selank and epitalonNone

3 ingredients · 4.5 mg on the label

Never tested as a combination

DSIP2 mg · 44% of the weight
The only part with sleep evidence, from a 1981 Lancet report and a 1987 study with a dummy group. Neither has been repeated since.
Epitalon2 mg · 44% of the weight
A small lab made pineal peptide with no proper human sleep trial. Its human record is Russian anti ageing studies.
Selank0.5 mg · 11% of the weight
The smallest share and the best clinical record, in anxiety. Its trial also reported stimulant effects.

What is known: DSIP has two human sleep studies from the 1980s and nothing since. Selank has a 62 patient trial against another drug in anxiety and nervous exhaustion. Epitalon has review summaries of cell work and Russian clinical work, not a proper human trial.
The catch: Eighty nine percent of the peptide weight is the two parts with no modern sleep evidence. The other eleven percent is the one part with a real clinical trial, and that trial reported stimulant effects, in a product sold for sleep. The DSIP evidence is not missing so much as frozen. It was positive in 1981 and 1987 and never tried again, most likely because nobody can own the result.

NAD+ with glutathioneNone

2 ingredients · no consistent label weight

Never tested as a combination

NAD+amount not sourced
Commonly supplied at 200 mg/mL. The human evidence is mostly about pills the body turns into NAD, where blood NAD roughly doubled once levels settled.
Glutathioneamount not sourced
Commonly supplied at 200 mg/mL. Its one trial with a dummy group, in Parkinson's disease, found no real difference.

What is known: In healthy volunteers, nicotinamide riboside pills raised blood NAD+ by 100% once levels settled, and the rise in NR tracked closely with the rise in NAD+. Glutathione by drip, 1,400 mg three times a week for four weeks, was given to 21 people with Parkinson's. It was well tolerated and made no real difference to symptom scores.
The catch: These are usually two separate drips given in one clinic visit, not one premixed product. There is no standard ratio, so no combined math is given here. The NAD result is a stand in: blood NAD can be raised, and nothing that follows from that has been shown in people. The glutathione result found no effect. And the most common thing anyone reports about these visits is chest tightness and nausea from a fast drip, which comes from the drip speed.

MOTS-c with SS-31None

2 ingredients · no consistent label weight

Never tested as a combination

MOTS-camount not sourced
No human trial of any kind. The studies are in mice made obese by diet, and the senior author has a declared business interest.
SS-31 (elamipretide)amount not sourced
A real drug still in testing. Its large final stage trial did not show a real benefit in the whole group studied.

What is known: MMPOWER-3 did not show a real benefit of elamipretide in adults with a muscle disease of the cell's power plants, across many different gene causes. When researchers looked back at smaller groups afterwards, one genetic group walked 25.2 metres farther in six minutes, against 2.0 metres on the dummy shot, and that gap was borderline. A group with a slowly worsening weakness of the eye muscles walked 37.3 metres farther, against a 8.0 metre drop, a clearer gap. MOTS-c has mouse data only.
The catch: The subgroup results apply to people with specific genetic diseases of the cell's power plants. That is not who buys a fatigue stack. The authors say these results only suggest ideas for a follow up trial. Sellers do not agree on vial sizes. To this blend's credit, the two parts really do work in different ways. That is a better start than most blends here, and it is still a start, not a finding.

Mitochondrial+ blendNone

3 ingredients · 55 mg on the label

Never tested as a combination

MOTS-c30 mg · 55% of the weight
54.5% of the vial by weight, and the part with no human trial at all.
TB-50016 mg · 29% of the weight
29.1% of the vial. A repair piece with no known link to the cell's power plants and no human study by any route.
SS-31 (elamipretide)9 mg · 16% of the weight
16.4% of the vial, and the only part to finish a large final stage trial program.

What is known: Elamipretide's large final stage trial in a muscle disease of the cell's power plants did not show a real benefit overall. Some genetic subgroups did better when researchers looked back afterwards. MOTS-c has mouse studies of body chemistry. The piece sold as TB-500 was found by a drug testing lab to be seven amino acids of thymosin beta 4, and it has no human study.
The catch: The ratio flips the product. The part with a finished large final stage program is the smallest share, at 16.4%. The part with no human data is the largest, at 54.5%. Mixed with 5 mL of water, one unit carries 60 micrograms of MOTS-c, 32 of the repair piece and 18 of SS-31. No published reason explains why a repair peptide with no link to the cell's power plants is nearly a third of a power plant product.

5-amino-1MQ with SLU-PP-332None

2 ingredients · 50.25 mg on the label

Never tested as a combination

5-amino-1MQ50 mg · 100% of the weight
99.5% of the active content. It blocks an enzyme called NNMT. It reversed obesity from a high fat diet in mice and has never been given to a person in a published study.
SLU-PP-3320.25 mg · 0% of the weight
It turns on a family of energy switches called ERRs. It raised the number of endurance muscle fibres and boosted endurance in mice. No human data of any kind.

What is known: Both ways of working are shown in cells and rodents. NNMT blockers raised NAD+ inside fat cells in a dish and lowered a waste molecule called 1-methylnicotinamide. They reversed diet driven obesity in mice. SLU-PP-332 raised type IIa endurance muscle fibres and exercise endurance in mice, through a program that depends on ERR alpha.
The catch: Neither drug has a published human study of any kind, not even on how the body handles it. So nothing is known about absorption at these doses. The 200 to 1 ratio means a buyer who came for the exercise in a pill is swallowing a quarter of a milligram of it, alongside fifty milligrams of something else. A common tablet version adds 125 micrograms of BPC-157. That is 0.25% of the tablet, by mouth, with no absorption data, for a peptide the FDA found had no adequate human data.

Thymosin alpha-1 with KPV and LL-37None

3 ingredients · no consistent label weight

Never tested as a combination

Thymosin alpha-1amount not sourced
The part with the largest trial, and it was negative. In 1,106 adults with sepsis, 23.4% died by day 28 on the drug, against 24.1% on the dummy.
KPVamount not sourced
No human data of any kind and no registered study. Mice with an inflamed gut, and cells in a dish.
LL-37amount not sourced
The best record of the three, on wounds, as a gel on the skin. More was not better: the strongest dose did no better than the dummy.

What is known: Thymosin alpha-1 had the biggest trial. It did not cut deaths at 28 days in a large final stage sepsis trial of 1,106 people. LL-37 was put on hard to heal leg ulcers in 34 people. At 0.5 and 1.6 mg/mL, the healing rate was about six times and three times higher than on the dummy. Average ulcer size fell 68% and 50%. At 3.2 mg/mL there was no difference from the dummy. A later trial studied LL-37 cream in diabetic foot ulcers.
The catch: The LL-37 evidence is from a gel on open wounds, at set strengths. This product is injected, for an effect on the whole immune system. The dose results on wounds did not rise in a straight line. That undercuts the usual blend idea that more of a good ingredient is better. One part calms inflammation, one boosts the immune system, and one both kills germs and can stir up inflammation, depending on the setting. Nobody has checked whether those effects add up or cancel out. There is no standard vial split.

Thymalin with epitalonNone

2 ingredients · no consistent label weight

Tested as a combination

Thymalinamount not sourced
An extract of calf thymus, not a single defined peptide. That is part of why the results are hard to repeat.
Epitalonamount not sourced
The lab made pineal peptide sold today. The death rate study used epithalamin, an extract of pineal gland, which is a different substance.

What is known: 266 older people were followed for six to eight years. They got thymalin and epithalamin during the first two to three years. Colds and chest infections fell 2.0 to 2.4 times. Deaths fell 2.0 to 2.1 times with thymalin, 1.6 to 1.8 times with epithalamin and 2.5 times with both. A smaller group given both every year for six years had a death rate 4.1 times lower than the comparison group.
The catch: The flag says the mix was tested, and the finding is still not settled. The report comes from one research group. It does not say that anyone was kept from knowing who got what, or that people were put into groups by chance. It does not explain how the comparison group was chosen. No outside group has repeated it in twenty years. Separately, the pineal part studied was epithalamin, a gland extract. What is sold today is epitalon, a lab made peptide. So a buyer quoting the death figures has swapped one substance for another. For comparison, a defined thymus peptide tested properly in 1,106 adults with sepsis found deaths about the same as on the dummy, a ratio of 0.99.

What a blend costs you, in 4 parts

Convenience is the honest argument for a blend: one vial, one draw, one mixing step. These are the things you give up for it, and none of them show when you buy.

01
You cannot adjust one ingredient on its own
Whoever filled the vial set the ratio. Every change you make to the draw moves all of the ingredients at once, in the amounts somebody else chose. The only dose decision left to you is how much of their mix to take.
02
You cannot stop one when a side effect appears
A reaction to one ingredient ends the whole vial, because there is no way to take one ingredient back out of the liquid. With separate vials, the same reaction costs you one compound and tells you which one it was.
03
You cannot tell what caused a benefit or a harm
If something improves, the blend gets the credit and you learn nothing you can use next time. If a blood marker moves the wrong way, you cannot say which ingredient moved it. That is the one piece of information that would have been worth the money.
04
The heaviest ingredient takes over the vial
Milligrams are not split evenly. In several of these, the ingredient with the most weight on the label is not the one in the marketing. So most of what you inject is whatever the maker loaded the vial with, whether or not it is the reason you bought it.

Doing the math on a blend

One strength figure means nothing for a vial with several compounds in it. Each ingredient is there at a different amount, so each one has a different strength in the same millilitre. Blend mode in the calculator takes the ingredient amounts printed on the label, the bacteriostatic water you added and the draw you plan. It gives what every ingredient delivers in that one draw, separately. It is math, never a dose: every number that produces a result comes from you.

6 of the 39 blends here have their label amounts stored as a calculator preset, so the ingredient fields are filled in for you: KLOW, GLOW, Wolverine, CJC-1295 with ipamorelin, Tesamorelin with ipamorelin, Sermorelin with a GHRP. For the rest, open blend mode and type the amounts from your own label.

Open the calculator KLOW GLOW Wolverine CJC-1295 with ipamorelin Tesamorelin with ipamorelin Sermorelin with a GHRP

Questions people ask about this

Has anyone tested these blends as blends?: Almost none of them. Of the 39 mixed vials listed here, 3 was tested as a product instead of pieced together from its parts. That one is a licensed testosterone product that mixes several forms of testosterone (esters), not a peptide blend. For the other 36, every claim made for the mix is borrowed from studies of each ingredient on its own.
If each ingredient has evidence, does the blend have evidence?: No. Evidence for A and evidence for B is not evidence for A plus B. It says nothing about whether the two stay stable in one vial, whether their effects add up, cancel out or overlap, what ratio would be right, or what happens to side effects when both arrive at once. A study of the mix exists to answer those questions, and for these products nobody ran one.
Why does the mass share matter?: Because it tells you what you are mostly injecting. A vial can list four ingredients and still be, by weight, one ingredient with three garnishes. The share on each card below is worked out from the label amounts, so you can see what the vial is mostly made of before you read what it is sold for.
How do I work out what one draw delivers from a blend?: Use blend mode in the reconstitution calculator. It takes each ingredient's label amount, the water you added and the draw you plan, and gives the amount of every ingredient in that draw separately. One strength figure means nothing when the vial holds several compounds at different amounts.
Why are some vial amounts missing here?: Because sellers do not agree on them. 22 of the 39 have no vial size consistent enough to quote, so the amount is left blank rather than invented. A made-up milligram figure would produce a made-up mass share, and the share is the part of this page worth reading.

36 of these 39 vials have never been tested as a vial

The 39 blends, and what is in them

What a blend costs you, in 4 parts

You cannot adjust one ingredient on its own

You cannot stop one when a side effect appears

You cannot tell what caused a benefit or a harm

The heaviest ingredient takes over the vial

Doing the math on a blend

Questions people ask about this